TheStreet’s Jim Cramer is keeping an eye on Allergan (AGN) Wednesday when the pharmaceutical giant releases its third quarter earnings results before the opening bell. Analysts are expecting Allergan to post earnings of $3.19 a share on $4.03 billion for the quarter. Cramer says, ‘this is going to be a difficult quarter because obviously they can’t talk about any talks they’ve had with Pfizer (PFE) and that’s really the elephant in the room.’ Cramer thinks the company is going to post good numbers, ‘I think they’re going to say, look we haven’t been able to explain exactly what the company looks like yet because we haven’t offloaded our generic business to Teva. So therefore I think that people are going to be disappointed because they can’t give you the guidance they would like because they haven’t offloaded the Teva, which is 40 billion dollars worth, and they’re going to be disappointed that you can’t pin them down on Pfizer.’ Cramer advises investors to buy Allergan if the stock comes down, ‘I’m not rooting for disappointment, I think the company is terrific, but I am saying people are going to be let down that they can’t talk about the divestiture yet of the generic and they can’t talk about Pfizer so people want to hear those things and they’re not going to hear them so therefore I think they’ll sell no matter how good the quarter is.’
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
